Clinical trial · Interventional
Establishment of Pancreas Cancer and Cancer-associated Fibroblast Using EUS-guided Biopsy Samples
Simultaneous Establishment of Pancreas Cancer and Cancer-associated Fibroblast Using EUS-guided Biopsy Samples
NCT05571956CI-TRIAL-00061341unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Organoid has emerged as the novel platform for preclinical anticancer drug testing in pancreatic ductal adenocarcinoma (PDA). However, most organoid models are not reconstituted with a tumor microenvironment. This study aimed to simultaneously establish PDA organoids and cancer-associated fibroblasts (CAFs) using endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) samples.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Adenocarcinoma | Pancreatic Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group
- description
- If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs u
- interventionNames
- Other: Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group
Primary outcomes (1)
- measure
- simultaneous establishment of pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts
- timeFrame
- From the EUS-FNB procedure til 2 weeks after EUS-FNB
- description
- The proportion of patients with successful establishment of pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * solid pancreatic mass lesion presumed PDA on cross-sectional imaging, regardless of tumor resectability Exclusion Criteria: * inability to provide informed consent, or coagulopathy (international normalized ratio \>1.5, platelet count \<50,000 per mcL)
References
Publications (0)
Data not yet available
No reference posted for this study.